{"id":11700,"date":"2021-06-29T13:14:50","date_gmt":"2021-06-29T18:14:50","guid":{"rendered":"https:\/\/cdtrp.ca\/?page_id=11700"},"modified":"2024-04-29T17:26:06","modified_gmt":"2024-04-29T21:26:06","slug":"covid-19-vaccination-in-transplant-recipients-cdtrp-national-initiative","status":"publish","type":"page","link":"https:\/\/cdtrp.ca\/en\/publications\/covid-19-vaccination-in-transplant-recipients-cdtrp-national-initiative\/","title":{"rendered":"COVID-19 Vaccination in Transplant Recipients: CDTRP National Initiative"},"content":{"rendered":"

The challenges of the pandemic have been particularly acute for transplant recipients. As vaccination programs begin rolling out across the country, there remain many unanswered research questions about COVID-19 vaccination in this population, who were excluded from all of the initial clinical trials. Over the last few months, CDTRP has been working to connect, mobilize, and align our community to identify and address these urgent issues.<\/p>\n

These discussions culminated in a large national research proposal (PRospective Evaluation of COVID-19 Vaccine in Transplant Recipients<\/a> (PREVenT-COVID<\/strong>): A National Strategy) submitted to the COVID-19 Immunity Task Force<\/u> (CITF) for funding. Research teams in Vancouver, Edmonton, London, Toronto, Montreal, and Quebec City, through a collaboration led by Dr. Deepali Kumar (University Health Network) and supported by the CDTRP network infrastructure, proposed a set of immunogenicity studies and a national safety surveillance study in transplant recipients.<\/div>\n<\/div>
<\/div>
<\/div><\/div>
<\/div>
We are delighted to share the news that we have been awarded funding by the CITF<\/strong> to undertake this work. As the work will move forward very quickly, given the pace of vaccination programs rolling out across the country, we will keep the community regularly informed of progress.<\/h5>\n<\/div>
<\/div>
<\/div><\/div>
<\/div>

The national safety surveillance study will be conducted in partnership with the\u00a0Canadian National Vaccine Safety (CANVAS)<\/u>. CANVAS is monitoring COVID-19 safety in the general public across Canada, with different regional approaches to recruitment, and a standardized set of REB-approved questionnaires.<\/p>\n

You can download all the Workshop reports below.<\/strong><\/p>\n<\/div>

<\/div><\/div><\/div><\/div><\/div>

<\/i><\/i><\/span>Expert Panel Meeting - January 6, 2021<\/span><\/a><\/h4><\/div>
\n

On January 6, 2021, CDTRP convened an Expert Panel<\/strong>\u00a0in the fields of solid organ and stem cell transplantation, transplant infectious diseases, immunization, public health, and patient partners to identify critical knowledge gaps around vaccination for COVID-19 in transplant recipients. The Panel produced a\u00a0report that can be downloaded below.<\/p>\n

Download the Expert Panel Report<\/a>.<\/strong><\/h5>\n<\/div><\/div><\/div><\/div><\/div>

<\/i><\/i><\/span>National Stakeholder Workshop - January 29, 2021<\/span><\/a><\/h4><\/div>
\n

The Expert Panel report formed the backbone for the agenda of a\u00a0National Stakeholder Workshop held January 29, 2021<\/strong>. We were delighted to have over 30 stakeholder organizations contribute, including the not-for-profit, government, and health care sectors, as well as public health, patients\/families, and professional societies. The workshop focused on how to prioritize the research studied identified, assembling a Knowledge Generation Roadmap.\u00a0The Workshop Report can be found below.<\/p>\n

Download the National Stakeholder Workshop report.<\/a><\/strong><\/h5>\n<\/div><\/div><\/div><\/div><\/div>

<\/i><\/i><\/span>Communication of Research with Patients and Families Workshop - April 23, 2021<\/span><\/a><\/h4><\/div>
\n

On April 23, 2021, CDTRP hosted a\u00a0National Workshop<\/strong>, focused on communication of research with patients and families, which included 18 patient, family, and donor partners and representatives from partner organizations with education or communications roles.<\/p>\n

The workshop\u2019s central objective was to develop consensus answers to two fundamental questions on COVID-19 vaccination in transplant participants:<\/p>\n